Tyra Biosciences has dosed the first paediatric participant in the dose-escalation/dose-expansion Phase II BEACH301 trial of ...

As regulators push to phase out animal testing, Charles River’s Steve Bulera notes that widespread implementation of ...

Dynavax has revealed outcomes from the initial part of its Phase I/II trial, comparing its shingles vaccine Z-1018 against ...

This webinar offers essential tools and insights to help organisations confidently navigate the BioSecure Act, ensuring they ...

If approved, AbbVie's Rinvoq could be set to dominate the alopecia market after exhibiting better efficacy than main ...